XML 57 R45.htm IDEA: XBRL DOCUMENT v3.25.2
Other Operating Income And Expenses (Tables)
 6 Months Ended
Jun. 30, 2025
Analysis of income and expense [abstract]  
Schedule of Other Operating Expenses
Other operating expenses for the first half of 2025 included €2,331 million of expenses related to Regeneron (compared with €1,841 million in the first half of 2024), as shown in the table below.
(€ million)June 30, 2025 (6 months)June 30, 2024 (6 months)
Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance(2,475)(1,934)
Additional share of profit paid by Regeneron towards development costs494 389 
Reimbursement to Regeneron of selling expenses incurred(346)(292)
Total: Monoclonal Antibody Alliance(2,327)(1,837)
Other (mainly Zaltrap and Libtayo)
66 92 
Other operating income/(expenses), net related to Regeneron (2,261)(1,745)
of which amount presented in “Other operating income” 70 96